Welcome to Bioconjugation Insights

I am delighted to welcome you to the first issue of Bioconjugation Insights!

This new journal marks a significant expansion of BioInsights’ mission to provide strategic, technical, and scientific clarity across today’s most dynamic therapeutic development frontiers. While we have touched on bioconjugation within our other journals, we now recognize the need for a dedicated platform that fully reflects the scope, complexity, and accelerating momentum of this field.

Bioconjugation represents an inter­section of biology and chemistry that continues to redefine drug discovery, targeted delivery, and diagnostics. While ADCs may have captured the spotlight in recent years, we are only just beginning to tap into the full potential of this modality-rich area. From antibody-oligonucleotide conjugates to radioconjugates, polymer conjugates, and cutting-edge theranostics, the field continues to rapidly evolve.

Bioconjugation Insights is designed to bring together experts from across the academic, biotech, pharma, and tools sectors to share actionable, up-to-date knowledge. Through this, the journal aims to cover everything from discovery through regulation and commercialization, supporting those on the front lines of R&D as well as those in the preclinical and clinical settings.

For our launch edition, we have curated a series of contributions that set the scene for key updates in the field and what lies ahead, through the perspectives of some of the foremost thought leaders working in bioconjugation today. This includes viewpoint articles from Rakesh Dixit (Cofounder, President and CSO of Regio Biosciences, CEO of Bionavigen, and CSO of Tmab Therapeutics) and Moein Moghimi (Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, and Research Professor, Institute of Cellular Medicine, Newcastle University; and Adjoint Professor, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center) who discuss finding the balance between safety and efficacy in ADCs, and how conjugates can be utilized to address the shortfalls of lipid nanoparticles, respectively.

The issue also includes a series of interviews with Helen Bright (CSO, Centauri Therapeutics), Michelle Morrow (CSO, Avacta Therapeutics), and Yu-Tzu Tai (Associate Director, ADC & Translational Research, Oxford Biotherapeutics). While Bright and Morrow discuss the use of peptide- and small peptide-conjugates in cancer therapies, Tai explores the future of ADCs through the translation of research into therapeutics.

Additionally, the journal also marks the launch of our newest article format, Industry Insights. These are concise articles, published once per issue, to highlight key updates in bioconjugations. They will cover the latest developments in collaborations, regulatory changes, marketing trends, and R&D in the field. Additionally, they will provide insights into key clinical trial results and recent innovations in tools and technology, and highlight notable conferences and publications. Going forward, Industry Insight articles will be contributed by our Editorial Advisory Board members.

We extend our sincere thanks to our Editorial Advisory Board and all those who have contributed their time, perspectives, and expertise.

I hope you enjoy this inaugural edition of Bioconjugation Insights—and that it becomes your go-to resource as this vital field continues to grow and evolve.

Lauren Coyle is Launch Commissioning Editor of Bioconjugation Insights